Get the Stockscreener App
8.54
2.89%
0.24
After Hours:
8.54
Fennec Pharmaceuticals Inc stock is traded at $8.54, with a volume of 112.81K.
It is up +2.89% in the last 24 hours and up +7.69% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$8.30
Open:
$8.46
24h Volume:
112.81K
Relative Volume:
1.29
Market Cap:
$229.51M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-14.00
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
+1.67%
1M Performance:
+7.69%
6M Performance:
+35.77%
1Y Performance:
+41.63%
1-Day Range:
$8.35
$8.61
1-Week Range:
$7.935
$8.61
52-Week Range:
$3.96
$8.72
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
8.54 | 229.51M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Bank of America Corp DE Has $226,000 Stock Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec's Pedmarqsi gets nod from U.K. regulators - MSN
(FENC) Investment Analysis and Advice - news.stocktradersdaily.com
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmac - GuruFocus
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus
Fennec Pharmaceuticals elects board members, shareholders approve proposals By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals elects board members, shareholders approve proposals - Investing.com
Fennec Pharmaceuticals Approves Proposals at Shareholder Meeting - TipRanks
Fennec Announces Results of Annual Meeting - TradingView
Northern Trust Corp Sells 2,976 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
FENC Meeting Scheduled in Toronto Hosted by Craig-Hallum | FENC Stock News - GuruFocus
How To Trade (FENC) - news.stocktradersdaily.com
Indian Pharma Co. Hit With Patent Suit Over Fennec's Cancer Drug - Law360
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Shares Acquired by BNP Paribas Financial Markets - Defense World
Q2 EPS Estimate for Fennec Pharmaceuticals Raised by Analyst - Defense World
HC Wainwright Brokers Increase Earnings Estimates for FENC - Defense World
FY2026 Earnings Estimate for TSE:FRX Issued By HC Wainwright - Defense World
Research Analysts Offer Predictions for FENC FY2026 Earnings - Defense World
Fennec Pharmaceuticals (NASDAQ:FENC) Earns Buy Rating from HC Wainwright - Defense World
Don't Ignore The Insider Selling In Fennec Pharmaceuticals - simplywall.st
Fennec Pharmaceuticals (TSE:FRX) Reaches New 12-Month High on Insider Buying Activity - Defense World
Fennec Pharmaceuticals at BioConnect: Strategic Moves and Market Expansion By Investing.com - Investing.com Canada
FENC: HC Wainwright Maintains "Buy" Rating and Price Target | FENC Stock News - GuruFocus
Fennec Pharma stock soars to 52-week high of $7.66 - Investing.com Australia
Insider Buying: Jeffrey Hackman Acquires 15,000 Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus
Fennec Pharma stock soars to 52-week high of $7.66 By Investing.com - Investing.com India
(FENC) Long Term Investment Analysis - news.stocktradersdaily.com
Wedbush Forecasts Higher Earnings for Fennec Pharmaceuticals - Defense World
Wedbush Raises Earnings Estimates for Fennec Pharmaceuticals - Defense World
Fennec Pharmaceuticals’ Earnings Call Highlights Growth and Expansion - TipRanks
Fennec Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
FENC: Craig-Hallum Raises Price Target for Fennec Pharmaceuticals | FENC Stock News - GuruFocus
Fennec (FENC) Receives Increased Price Target from Craig-Hallum - GuruFocus
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Call Transcript - Insider Monkey
Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World
Fennec Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Fennec Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Fennec Pharmaceuticals Q1 Product Sales USD 8.8 Million - marketscreener.com
FENC Reports Strong Q1 Revenue Surpassing Expectations | FENC St - GuruFocus
Fennec Pharmaceuticals Sees Revenue Surge with Strategic Expansion in Europe - TipRanks
FENNEC PHARMACEUTICALS Earnings Results: $FENC Reports Quarterly Earnings - Nasdaq
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Fennec Pharmaceuticals Brief: Q1 Basic and Diluted Loss Per Common Share US$0.04 - marketscreener.com
Barclays PLC Grows Stock Position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Wells Fargo & Company MN Has $83,000 Position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals (FENC) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times
When (FENC) Moves Investors should Listen - news.stocktradersdaily.com
Recent uptick might appease Fennec Pharmaceuticals Inc. (NASDAQ:FENC) hedge funds owners after losing 32% over the past year - Yahoo Finance
Geode Capital Management LLC Raises Position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):